Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Erika Vance

Nurse Practitioner, Family Jonesboro, AR Nurse Practitioner

NPI 1366816670 CMS profile 10667042

2205 W Parker Rd, Jonesboro, AR 72404

Open in the dashboard

General payments

$10,231

694 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erika Vance of Jonesboro, AR is reported in the CMS Open Payments database as having received $10,231 across 694 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,050 132
2024 General $2,207 149
2023 General $2,189 136
2022 General $1,786 128
2021 General $2,000 149

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erika Vance
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Erika Vance were reported at $2,050. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Erika Vance Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,000 $124 $35–$379 $132
2022 $1,786 $141 $44–$430 $149
2023 $2,189 $154 $49–$476 $160
2024 $2,207 $165 $51–$504 $164
2025 $2,050 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,292 102 payments
  2. Pfizer Inc. $1,096 89 payments
  3. AstraZeneca Pharmaceuticals LP $923 40 payments
  4. Lilly USA, LLC $807 66 payments
  5. Novo Nordisk Inc $797 58 payments
  6. GlaxoSmithKline, LLC. $651 46 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $495 30 payments
  8. Otsuka America Pharmaceutical, Inc. $453 22 payments
  9. Amgen Inc. $350 29 payments
  10. Merck Sharp & Dohme Corporation $339 25 payments
  11. Other $3,029 187 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,022 692 payments
  2. Education $209 2 payments
Products named General payments · program years 2021–2025
  1. NURTEC ODT $948 78 payments
  2. UBRELVY $682 55 payments
  3. ZAVZPRET $595 51 payments
  4. FARXIGA $534 22 payments
  5. TRELEGY ELLIPTA $521 42 payments
  6. Ozempic $510 35 payments
  7. RYBELSUS $510 35 payments
  8. BREZTRI $470 11 payments
  9. TRINTELLIX $463 28 payments
  10. REXULTI $453 22 payments
  11. Other $8,508 601 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 109 drugs

Part D claims

4,248

Median for Nurse Practitioner: 389

Drug cost

$316,260

Median for Nurse Practitioner: $21,885

Branded share of claims

20.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 49 $54,222
Ozempic Semaglutide Brand 42 $48,576
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 44 $31,512
Januvia Sitagliptin Phosphate Brand 42 $31,434
Eliquis Apixaban Brand 32 $23,361
Jardiance Empagliflozin Brand 20 $20,944
Xarelto Rivaroxaban Brand 20 $15,389
Linzess Linaclotide Brand 15 $15,179
Entresto Sacubitril/Valsartan Brand 17 $8,495
Tresiba Flextouch U-200 Insulin Degludec Brand 12 $7,017

The 10 drugs with the highest cost, of 109 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$79,530

Of which drugs: $16,805

Medicare patients

411

Average age 75

Services billed

10,416

273 women, 138 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 35%
Ischemic heart disease 33%
Depression 33%
Osteoporosis 26%
Heart failure 22%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 11 660 $13,245
Vaccine for influenza for injection into muscle 90662 Office 19 19 $1,510
Injection, methylprednisolone acetate, 1 mg J1010 Office 62 2,881 $258
Injection, methylprednisolone acetate, 40 mg J1030 Office 34 36 $96
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 25 62 $53
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 81 416 $26

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $139
  • Otsuka America Pharmaceutical, Inc. $123
$262 — —
UBRELVY
  • AbbVie, Inc. $159
$159 — —
NURTEC ODT
  • PFIZER INC. $126
$126 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $125
$125 — —
MOUNJARO
  • Lilly USA, LLC $104
$104 49 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

694 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record